Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.41 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| REGN | VIG | |
|---|---|---|
Market Cap | $76.40B | $132.40B |
Volume | 626,381 | 1,733,469 |
Sector | Health | — |
52-Week High | $852.03 | $246.61 |
52-Week Low | $557.73 | $210.70 |
Typical Hold Time | 107 Days | 133 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
VIG trades at $236.99, down 0.32% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic positioning for long-term income investors.
VIG presents a compelling option for investors seeking dividend growth with moderate risk, though its low current yield may not suit income-focused portfolios. Key risks include market volatility and the ETF's exclusion of high-yield dividend payers. Analyst sentiment remains positive given its historical 10% annual returns and quality screening criteria.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
